The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...

To mitigate this risk, Cigna will need to focus on effective cost management strategies, such as negotiating favorable contracts with drug manufacturers ... landscape or pricing pressures could ...

The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs ...

Cigna is building on client demand for tools to support patients on GLP-1 weight loss drugs, announcing two new programs on Friday meant to improve clinical care around the dispensing of GLP-1s ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

On Friday, UBS analyst AJ Rice confirmed a Buy rating for Cigna (NYSE: CI) shares, maintaining the $390.00 price target.Rice provided insights following a recent investor event at the Evernorth ...

Ladies and gentlemen, thank you for standing by for the Cigna Group's First Quarter ... the lower prices we negotiate for high list price branded drugs. For example, we will process over 2 billion ...

CEO Andrew Witty this week has sent shockwaves through an already tumultuous healthcare sector. Investors in UNH stock have certainly had plenty of headwinds to deal with over the course of the past ...

Sen. Josh Hawley, R-Mo., demanded Tuesday that Congress move to stop insurance companies from owning pharmacy benefit ...